GlobeNewswire
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
📊
AI Sentiment
Positive
7/10
- Home
- FDMT
as of 12-12-2025 3:58pm EST
$10.86
$0.06
-0.56%
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Chart Type:
Time Range:
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 391.8M | IPO Year: | 2020 |
| Target Price: | $30.33 | AVG Volume (30 days): | 767.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $12.34 | Next Earning Date: | 11-10-2025 |
| Revenue: | $120,000 | Revenue Growth: | 605.88% |
| Revenue Growth (this year): | 21181.08% | Revenue Growth (next year): | 162.43% |
AI-Powered FDMT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 77.85%
77.85%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of 4D Molecular Therapeutics Inc. (FDMT)
Bizily Scott
Sell
Chief Legal Officer
FDMT Nov 17, 2025
Avg Cost/Share
$10.59
Shares
1,635
Total Value
$17,314.65
Owned After
3,594
SEC Form 4
Bizily Scott
Sell
Chief Legal Officer
FDMT Oct 24, 2025
Avg Cost/Share
$12.00
Shares
2,678
Total Value
$32,136.00
Owned After
3,594
SEC Form 4
Bizily Scott
Sell
Chief Legal Officer
FDMT Oct 16, 2025
Avg Cost/Share
$10.17
Shares
1,635
Total Value
$16,627.95
Owned After
3,594
SEC Form 4
Bizily Scott
Sell
Chief Legal Officer
FDMT Oct 9, 2025
Avg Cost/Share
$10.00
Shares
2,408
Total Value
$24,080.00
Owned After
3,594
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bizily Scott | FDMT | Chief Legal Officer | Nov 17, 2025 | Sell | $10.59 | 1,635 | $17,314.65 | 3,594 | |
| Bizily Scott | FDMT | Chief Legal Officer | Oct 24, 2025 | Sell | $12.00 | 2,678 | $32,136.00 | 3,594 | |
| Bizily Scott | FDMT | Chief Legal Officer | Oct 16, 2025 | Sell | $10.17 | 1,635 | $16,627.95 | 3,594 | |
| Bizily Scott | FDMT | Chief Legal Officer | Oct 9, 2025 | Sell | $10.00 | 2,408 | $24,080.00 | 3,594 |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
Compare FDMT vs Leading Stocks
See how FDMT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.